Worldwide, obesity has become a major risk factor associated with health risks such as diabetes, hypertension, hypercholesterolemia, cardiovascular disease, stroke, and certain forms of cancer. In this study, we estimated the anti-obesity effect of the bacterial strain Lactobacillus plantarum LB818 (designated as LB818) using male C57BL/6J mice, which were treated with high-fat diet (HFD) to induce obesity. Next, LB818 (10⁹ colony-forming units [CFU]/mL) was orally administered for 8 weeks. The results showed that feeding HFD+LB818 (10⁹ CFU/mL) ameliorated body weight gain and decreased total body fat by regulating fasting glucose levels in HFD-fed mice. LB818 treatment significantly lowered aspartate aminotransferase, alanine aminotransferase (ALT), total cholesterol (TC), triglyceride (TG), and elevated high-density lipoprotein levels in serum and decreased deposition of fat droplets in liver. LB818 treatment increased the respective abundances of essential bacteria, including Bacteroidetes, Akkermansia, Bifidobacterium, Lactobacillus, and increased the Bacteroidetes:Firmicutes ratio; however, it significantly decreased the levels of Firmicutes. Taken together, this study demonstrates that LB818 is effective in attenuating obesity and hepatic steatosis and regulated gut microbiota in HFD-fed obese mice.

中文翻译：

---

植物乳杆菌LB818的抗肥胖作用与高脂饮食喂养的肥胖小鼠肠道菌群的调节有关。

在世界范围内，肥胖已成为与健康风险（例如糖尿病，高血压，高胆固醇血症，心血管疾病，中风和某些形式的癌症）相关的主要危险因素。在这项研究中，我们估计了使用高脂饮食（HFD）诱导肥胖的雄性C57BL / 6J小鼠对植物乳杆菌LB818（命名为LB818）的抗肥胖作用。接下来，将LB818（10 ^9个菌落形成单位[CFU] / mL）口服施用8周。结果表明饲喂HFD + LB818（10 ⁹CFU / mL）通过调节HFD喂养的小鼠的空腹血糖水平，改善了体重增加并减少了体内总脂肪。LB818治疗可显着降低血清中的天冬氨酸转氨酶，丙氨酸转氨酶（ALT），总胆固醇（TC），甘油三酸酯（TG），并提高血清中高密度脂蛋白水平，并减少肝脏中脂肪滴的沉积。LB818处理增加了必需细菌的丰富度，其中包括拟杆菌，阿克曼菌，双歧杆菌，乳杆菌，并增加了拟杆菌：杀菌剂的比例；但是，它显着降低了Firmicutes的水平。两者合计，这项研究表明LB818在减轻肥胖和肝脂肪变性和HFD喂养的肥胖小鼠中调节肠道菌群方面是有效的。